Radnor Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Radnor Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-667	Closed	-$56K	–	182
2018 Q3	$56K	Hold	667	–	–	0.02%	180
2018 Q2	$64K	Hold	667	–	–	0.02%	173
2018 Q1	$70K	Hold	667	–	–	0.02%	176
2017 Q4	$104K	Buy	+667	New	+$85K	0.03%	178

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Radnor Capital Management's VRDN Position: Q4 2018 in Review

Radnor Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2018, closing a stake of 667 shares — an estimated $56K sold.

Radnor Capital Management first reported a position in VRDN in Q4 2017 and held it in 4 quarters. The position peaked at $104K in Q4 2017. 56 funds tracked by Wall St. Rank hold VRDN as of Q4 2018.

Radnor Capital Management reported no remaining Viridian Therapeutics position as of Q4 2018 after selling out during the quarter.
Radnor Capital Management sold 667 Viridian Therapeutics shares in Q4 2018, an estimated $56K.
Radnor Capital Management first reported a position in Viridian Therapeutics in Q4 2017 and held it in 4 quarters.
Radnor Capital Management's Viridian Therapeutics position peaked at $104K in Q4 2017.
56 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2018.

Based on Radnor Capital Management's 13F filing for Q4 2018, filed 16 Jan 2019.